PFE  Pfizer Inc.

Exchange

NYSE

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

211.99B

Vuru Grade

60.55/100

Current Price

$34.95
+0.13 (+0.37%)

Growth Price

$25.70
Overvalued by 26.47%

Stability Price

$11.98
Overvalued by 65.71%

Company Metrics

  • P/E 30.98
  • P/S 4.04
  • P/B 3.37
  • EPS 1.13
  • Cash ROIC 13.13%
  • Cash Ratio 0.79
  • Dividend 1.2 / 3.44%
  • Avg. Vol. 22.15M
  • Shares 6.07B
  • Market Cap. 211.99B

Company Description

Pfizer Inc., a biopharmaceutical company, offers prescription medicines for humans and animals worldwide. The company's Biopharmaceutical segment's provides Lipitor for elevated LDL-cholesterol levels in the blood; Enbrel for rheumatoid arthritis, polyarticular juvenile rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis; Lyrica for post-herpetic neuralgia, diab... more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Pfizer to Buy Antibiotics From AstraZeneca for $725 Million
Bloomberg - Aug 24, 2016
Pfizer Inc. agreed to buy an antibiotics business from AstraZeneca Plc for $725 million as well as other payouts, settling for one piece of a company it once tried to acquire.
Pfizer to buy rival's antibiotics rights - Press Herald
Pfizer's $1.5 Billion Antibiotics Buy: Strategic Long-Term Planning Or Pre ... - Benzinga
Pfizer And Medivation: A Good Strategic Fit
Seeking Alpha - 7 hours ago
Pfizer (NYSE:PFE) is taking the route of in-organic growth in order to enhance its falling revenues. The company has been extremely active in the M&A world and it has added some interesting drugs to the portfolio.
Pfizer Inc. (NYSE:PFE) Receives Consensus Rating of "Buy" from Brokerages - The Cerbat Gem
Pfizer Inc. (NYSE:PFE) Buys BIND's Assets - LearnBonds
Most Recent analysts Ratings: Pfizer, Inc. (NYSE:PFE)
News Oracle - 7 hours ago
Pfizer, Inc. (NYSE:PFE) reported its last earnings on Aug 02 BMO (BMO = before market open, AMC= after market close).
Analysts Tips to Monitor: Pfizer, Inc. (NYSE:PFE) , SCYNEXIS, Inc. (NASDAQ:SCYX) - Street Updates
Pfizer Inc.: Medivation Acquisition Could Send Pfizer Stock Soaring
Profit Confidential - Aug 23, 2016
Pfizer Inc. (NYSE:PFE), the pharmaceutical giant behind such elevated brands as “Viagra,” has made a successful bid for Medivation Inc (NASDAQ:MDVN), with an offer of $14 billion.
Pfizer Inc. (NYSE:PFE): Analyst is Neutral to Positive on Medivation Inc ... - TCC
Pfizer-Medivation Deal: Good Or Bad For Shareholders?
Seeking Alpha - Aug 24, 2016
Medivation is an intriguing acquisition, and would then provide Pfizer with two strong brand-name cancer drugs (Xtandi, Ibrance) and complement the upcoming emergence of the company's immuno-oncology portfolio. Management's projections of a $0.05 ...
How Pfizer Inc. (NYSE:PFE) Makes A Comeback After It Was Written-Off? - InvestCorrectly
Pfizer Inc-Medivation Inc Deal To Drive More Biotech M&A - Bidness ETC
25% Return Left After Pfizer Deal
Seeking Alpha - Aug 24, 2016
Pfizer (NYSE:PFE) bought BIND's (NASDAQ:BIND) (BINDQ) assets out of bankruptcy. With no remaining operations, the company is liquidating. Shareholders can expect to get around $1.17, plus or minus $0.09 by around year-end. For details, here is the ...
BMO Capital Highlights Several Targets Following Pfizer Inc.'s Deal with ...
TCC - Aug 22, 2016
Considering Pfizer Inc.'s (NYSE:PFE) deal worth $14 billion in order to acquire Medivation Inc (NASDAQ:MDVN), analyst Do Kim at BMO Capital believes the deal has increased the attractiveness of the other mid-cap companies in the bio-tech segment.
Pfizer Inc. (PFE) Closes 0.77% Down on the Day for August 24
Equities.com - Aug 24, 2016
Dow Jones component Pfizer Inc. (PFE) saw its stock move -0.77% to $34.82, representing a per-share move of $0.27, on volume of 22.11 million shares for Wednesday.
Pfizer Inc. (NYSE:PFE) To Close Down Four Of Its Legacy Distribution Sites
Market Exclusive - Aug 19, 2016
Pfizer Inc. (NYSE:PFE) has opted to close down four of its legacy distribution units that it acquired in the buyout of Hospira last year.
Pfizer Inc. (NYSE: PFE) Buy Rating Reiterated at Deutsche Bank AG - BNB Daily (blog)
Activist Keith Meister Unloads Large Pfizer (PFE) Position, Takes Stakes in B ... - Insider Monkey (blog)
Pfizer Inc Stock Is Not A Buy Post Q2 Earnings
Amigobulls - Aug 9, 2016
Pfizer (NYSE:PFE) stock actually beat earnings estimates in its fiscal second quarter but that didn't keep the stock from falling once earnings were released.
Pfizer: Q2 2016 Progress Is Good, Headwinds Remain - Seeking Alpha